CADDRA 2021: 17th Annual ADHD Conference : 8th Annual ADHD Research Day

CADDRA 2021: 17th Annual ADHD Conference : 8th Annual ADHD Research Day is organized by Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) and will be held from Oct 01 - 03, 2021.

17th Annual CADDRA ADHD Conference - October 2 & October 3, 2021
Who Should Attend?
Psychiatrists, paediatricians, family physicians, psychologists, neurologists, nurse practitioners, nurses, social workers, other research and healthcare professionals and trainees
 
General Information:
The CADDRA conference is the only two-day national meeting in Canada showcasing the latest scientific, clinical and practical information on ADHD diagnosis, assessment and treatment in children, adolescents and adults.  Medical and health care professionals working in the field of ADHD will enhance their knowledge and skills by attending keynote talks, seminars, workshops and panel discussions during in the two-day meeting.

Overall learning objectives:
• Recognize the clinical implications of emotional dysregulation in ADHD.
• Explain how genomic data can or cannot be used to diagnose disorders or select treatments.
• Review data supporting the short- and long-term efficacy of stimulants.
• Assess data about the cost-effectiveness of stimulants.
• Identify the neurobiological basis of ADHD.
• Define the impact of treatments for ADHD on functional outcomes.

8th Annual ADHD Research Day - October 1, 2021
Who Should Attend?
Researchers, post doctorate fellows, students of all levels and health care professionals interested in ADHD research.

General Information
The day will focus on current ADHD research in Canada. Opprtunities for learning will include a keynote talk, a panel discussion, oral presentations by senior, junior and trainee researchers, and poster sessions.
 
Overall learning objectives:
• Recognize the clinical implications of emotional dysregulation in ADHD.
• Explain how genomic data can or cannot be used to diagnose disorders or select treatments.
• Review data supporting the short- and long-term efficacy of stimulants.
• Assess data about the cost-effectiveness of stimulants.
• Identify the neurobiological basis of ADHD.
• Define the impact of treatments for ADHD on functional outcomes.